Cargando…

Lopinavir/r no longer recommended as a first-line regimen: a comparative effectiveness analysis

INTRODUCTION: We compared the effectiveness of tenofovir/emtricitabine (TDF/FTC) combined with either lopinavir/r (LPV/r) or another recommended third drug in the 2010 French guidelines in antiretroviral-naïve patients starting combination antiretroviral therapy in 2004–2008 in the French Hospital D...

Descripción completa

Detalles Bibliográficos
Autores principales:	Potard, Valérie, Rey, David, Poizot-Martin, Isabelle, Mokhtari, Saadia, Pradier, Christian, Rozenbaum, Willy, Brun-Vezinet, Françoise, Costagliola, Dominique
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	International AIDS Society 2014
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4176690/ https://www.ncbi.nlm.nih.gov/pubmed/25261780 http://dx.doi.org/10.7448/IAS.17.1.19070

Ejemplares similares

Durability and Effectiveness of Maraviroc-Containing Regimens in HIV-1-Infected Individuals with Virological Failure in Routine Clinical Practice
por: Potard, Valérie, et al.
Publicado: (2015)

Impact of etravirine on hospitalization rate between 2005 and 2011 among heavily treated HIV-1-infected individuals on failing regimens
por: Potard, Valérie, et al.
Publicado: (2018)

Assessing the Efficacy of Lopinavir/Ritonavir-Based Preferred and Alternative Second-Line Regimens in HIV-Infected Patients: A Meta-Analysis of Key Evidence to Support WHO Recommendations
por: Huang, Yinqiu, et al.
Publicado: (2018)

First-line antiretroviral therapy with nevirapine versus lopinavir-ritonavir based regimens in a resource-limited setting
por: Clumeck, Nathan, et al.
Publicado: (2014)

Boosted lopinavir vs boosted atazanavir in patients failing a NNRTI first line regimen in an urban clinic in Kampala
por: Laker, Eva, et al.
Publicado: (2014)

Polymorphism in Gag Gene Cleavage Sites of HIV-1 Non-B Subtype and Virological Outcome of a First-Line Lopinavir/Ritonavir Single Drug Regimen
por: Ghosn, Jade, et al.
Publicado: (2011)

An observational study in an urban Ugandan clinic comparing virological outcomes of patients switched from first-line antiretroviral regimens to second-line regimens containing ritonavir-boosted atazanavir or ritonavir-boosted lopinavir
por: Laker, Eva Agnes Odongpiny, et al.
Publicado: (2019)

Virological outcomes in ARV-naïve patients switching or not from a first successful boosted PI-regimen to efavirenz, nevirapine or abacavir regimens
por: Bommenel, T, et al.
Publicado: (2010)

Lopinavir plus nucleoside reverse-transcriptase inhibitors, lopinavir plus raltegravir, or lopinavir monotherapy for second-line treatment of HIV (EARNEST): 144-week follow-up results from a randomised controlled trial
por: Hakim, James G, et al.
Publicado: (2018)

Effectiveness and tolerance of single tablet versus once daily multiple tablet regimens as first-line antiretroviral therapy - Results from a large french multicenter cohort study
por: Cotte, Laurent, et al.
Publicado: (2017)

First-line cART regimen impacts the course of CD8(+) T-cell counts in HIV-infected patients that achieve sustained undetectable viral load.
por: Poizot-Martin, Isabelle, et al.
Publicado: (2016)

Detection of Pandemic (H1N1) 2009 Virus in Patients Treated with Oseltamivir
por: Boutolleau, David, et al.
Publicado: (2010)

Role of Baseline HIV-1 DNA Level in Highly-Experienced Patients Receiving Raltegravir, Etravirine and Darunavir/Ritonavir Regimen (ANRS139 TRIO Trial)
por: Charpentier, Charlotte, et al.
Publicado: (2013)

Pediatric Systemic Lupus Erythematosus: Learning From Longer Follow Up to Adulthood
por: Costagliola, Giorgio, et al.
Publicado: (2018)

An open-label randomized controlled trial of the effect of lopinavir/ritonavir, lopinavir/ritonavir plus IFN-β-1a and hydroxychloroquine in hospitalized patients with COVID-19
por: Ader, Florence, et al.
Publicado: (2021)

Population pharmacokinetics of lopinavir/ritonavir in Covid-19 patients
por: Alvarez, Jean Claude, et al.
Publicado: (2020)

Role of Lopinavir/Ritonavir in the Treatment of Covid-19: A Review of Current Evidence, Guideline Recommendations, and Perspectives
por: Meini, Simone, et al.
Publicado: (2020)

Comparative efficacy and safety of regimens including ritonavir-boosted lopinavir or nevirapine in antiretroviral-naïve HIV-1-infected individuals
por: Pereira, A, et al.
Publicado: (2010)

Hepatitis C virus prevalence and genetic diversity among pregnant women in Gabon, central Africa
por: Ndong-Atome, Guy-Roger, et al.
Publicado: (2008)

Efficacy and safety of an NRTI-sparing regimen in antiretroviral-naïve HIV-infected patients: once-daily maraviroc plus lopinavir/ritonavir
por: Nozza, S, et al.
Publicado: (2010)

Minority M184V variants in women exposed to 3TC/FTC-containing lopinavir-ritonavir (LPVr) regimens in pregnancy
por: Surah, S, et al.
Publicado: (2010)

Lopinavir/ritonavir monotherapy in clinical practice
por: Caso, A, et al.
Publicado: (2010)

Lopinavir-Ritonavir-Kombination nicht wirksam
por: Diener, Hans-Christoph
Publicado: (2020)

Comparing albuvirtide plus ritonavir-boosted lopinavir regimen to two nucleotide reverse transcriptase inhibitors plus ritonavir-boosted lopinavir in HIV-infected individuals who failed initial treatment: a retrospective comparative cohort study
por: Chen, Liyu, et al.
Publicado: (2022)

Raltegravir Non-Inferior to Nucleoside Based Regimens in SECOND-LINE Therapy with Lopinavir/Ritonavir over 96 Weeks: A Randomised Open Label Study for the Treatment Of HIV-1 Infection
por: Amin, Janaki, et al.
Publicado: (2015)

Crushing lopinavir/ritonavir tablets does not result in lower exposure to lopinavir/ritonavir in adult patients with COVID-19
por: Mohsenian Naghani, Shaghayegh, et al.
Publicado: (2023)

Efficacy and safety of rilpivirine-based regimens in treatment-experienced HIV-1 infected patients: a prospective cohort study
por: Gazaignes, Sandrine, et al.
Publicado: (2014)

Long-term efficacy and toxicity of abacavir/lamivudine/nevirapine compared to the most prescribed ARV regimens before 2013 in a French Nationwide Cohort Study
por: de Boissieu, Paul, et al.
Publicado: (2016)

Correction: Raltegravir Non-Inferior to Nucleoside Based Regimens in SECOND-LINE Therapy with Lopinavir/Ritonavir over 96 Weeks: A Randomised Open Label Study for the Treatment Of HIV-1 Infection
por: Amin, Janaki, et al.
Publicado: (2015)

Outcomes of WHO-conforming, longer, all-oral multidrug-resistant TB regimens and analysis implications
por: Rich, M. L., et al.
Publicado: (2023)

Synthesis and Characterization of Impurities in the Production Process of Lopinavir
por: Raghava Reddy, Ambati V., et al.
Publicado: (2015)

Propofol/lopinavir/ritonavir: Bradyarrythmia: case report
Publicado: (2020)

Lopinavir: Various toxicities: 4 case reports
Publicado: (2020)

Abacavir Exposure in Children Cotreated for Tuberculosis with Rifampin and Superboosted Lopinavir-Ritonavir
por: Rabie, Helena, et al.
Publicado: (2020)

Efficient immune reconstitution in HIV+ naïve patients (pts) starting a first lopinavir/ritonavir-containing regimen with low CD4 counts
por: Merlini, E, et al.
Publicado: (2010)

Patients of COVID-19 may benefit from sustained Lopinavir-combined regimen and the increase of Eosinophil may predict the outcome of COVID-19 progression
por: Liu, Fang, et al.
Publicado: (2020)

Brief Report: Suboptimal Lopinavir Exposure in Infants on Rifampicin Treatment Receiving Double-dosed or Semisuperboosted Lopinavir/Ritonavir: Time for a Change
por: Jacobs, Tom G., et al.
Publicado: (2023)

Cost-effectiveness of atazanavir-ritonavir versus lopinavir-ritonavir in HIV patients initiating first-line antiretroviral therapy
por: Broder, MS, et al.
Publicado: (2010)

Bone mineral density in HIV participants randomized to raltegravir and lopinavir/ritonavir compared with standard second line therapy
por: Martin, Allison, et al.
Publicado: (2013)

HIV Viral Dynamics of Lopinavir/Ritonavir Monotherapy as Second-Line Treatment: A Prospective, Single-Arm Trial
por: Claassen, Cassidy W., et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_d4s0mvl0aadnehbp2qnfg3nefi